Recurrent mutations in chromatin modifiers are most frequently occurring in many cancers, such as activating mutations in enhancer of zeste homolog 2 (EZH2) and inactivating mutations in CREB Binding Protein (CREBBP)/E1A binding protein P300 (EP300), lysine Methyltransferase 2D (KMT2D), SET domain containing 2 (SETD2), AT-rich interaction domain 1A (ARID1A), isocitrate dehydrogenase type 2(IDH2) (Cheng et al., 2019), suggesting that these epigenetic modifiers are ideal targets in therapeutic approaches. This evidence concerns the gene EZH2 and cancer.